EGFR/COX-2-IN-3 

EGFR/COX-2-IN-3 is a selective EGFR/COX-2 dual inhibitor with IC₅₀ values of 0.098 μM and 0.05 μM, respectively. EGFR/COX-2-IN-3 is predicted to have oral activity and blood-brain barrier permeability. EGFR/COX-2-IN-3 exhibits both potent analgesic activity and anti-glioblastoma effects. EGFR/COX-2-IN-3 can be used in the research of tumors such as glioblastoma^[1].

EGFR/COX-2-IN-3 (Compound 10a) exhibits potent cytotoxicity against U-251 and SNB-75, with IC₅₀ values of 8.8 μM and 2.6 μM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

EGFR/COX-2-IN-3 exhibits analgesic activity in the mouse hot-plate test, with an AUC of 37.83, which is superior to that of Celecoxib (HY-14398)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

375.47

C₂₂H₂₅N₅O

O=C(CN1CCN(C)CC1)NC2=CC(C3=CC=CC=C3)=NN2C4=CC=CC=C4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Farag KO, et al. Pyrazole derivatives as dual COX-2/EGFR inhibitors with anticancer potential: Optimization of difenamizole Analogs. Bioorg Chem. 2026;170:109444.  [Content Brief]